


Maternal and child health

This brief summarizes the contributions of Kaiser Permanente Research since 2007 on the topic of maternal and child health, including prepregnancy risk factors and a variety of risks and outcomes occurring both during and following childbirth.

According to the Centers for Disease Control and Prevention (CDC), approximately 4 million babies are born in the United States each year.¹ Although most babies are healthy and born without complications, pregnancy carries risks for both mothers and infants, and high-quality care during the prenatal period is essential for ensuring positive perinatal and postnatal health outcomes. Many women have underlying health problems that may present challenges during pregnancy. More than half of women who become pregnant are overweight or obese,² and conditions such as diabetes and chronic hypertension are present in 1% to 2% of women at the time of conception.^{3,4} Moreover, recent data suggest that approximately 5% of pregnant women smoke,⁵ and nearly 10% consume alcohol.⁶ In addition, 8.5% of pregnant women report recent use of illicit drugs, with use of marijuana and opioids increasingly common.⁷ During pregnancy, approximately 2% to 10% of pregnant women experience gestational diabetes,⁸ and rates of both postpartum hemorrhage and hypertension have increased dramatically in recent years.⁹ Finally, about 10% of births in the U.S. are preterm,¹⁰ and over 8% are low-birthweight babies.¹¹ Preterm and low-weight births are each associated with serious long-term health consequences, including developmental delay, breathing problems, and infant mortality.

Maternal and child health is an active area of study for Kaiser Permanente Research. Scientists across the organization have used our rich, comprehensive, longitudinal data to advance knowledge in the areas of understanding risk, improving patient outcomes, and translating research findings into policy and practice. We have published more than 2,200 articles related to maternal and

Kaiser Permanente publications related to maternal and child health since 2007



Source: Kaiser Permanente Publications Library and Scite metrics, as of June 15, 2023.

child health since 2007;¹² together, these articles have been cited almost 95,000 times. These articles are the product of observational studies, randomized controlled trials, meta-analyses, and other studies led by Kaiser Permanente scientists. Our unique environment – a fully integrated care and coverage model in which our research scientists, clinicians, medical groups, and health plan leaders collaborate – lets us contribute generalizable knowledge on maternal and child health, and many other research topics.

Understanding Risk

For which health problems are mothers and newborn children at increased risk?

Mothers and newborns may experience a variety of unique health issues, and Kaiser Permanente researchers have studied potential risk factors associated with these conditions. Research conducted at Kaiser Permanente has linked prepregnancy obesity,¹³⁻¹⁵ hypertension,¹⁶ prediabetes,¹⁷ levels of particular metabolic proteins,¹⁸ and nonalcoholic fatty liver disease¹⁹ with the risk of gestational diabetes mellitus (GDM), which is, in turn, associated with risks to the child,^{20;21} including high birth weight,^{22;23} insulin resistance,^{24;25} asthma,²⁶ neonatal hypoglycemia, and elevated bilirubin.^{21;23} The cardiovascular health of mothers during pregnancy may influence both their own long-term cardiovascular health²⁷ and that of their children.²⁸ Maternal hypertension may increase the risk of congenital defects,²⁹ and women with higher prepregnancy cardiovascular risks^{30;31} and asthma³² are more likely to be diagnosed with preeclampsia. Recent work has also found that children born to women with type 2 diabetes may be at increased risk of developing asthma.²⁶ Pregnant women hospitalized for COVID-19 in 2020 had higher rates of prepregnancy obesity and GDM than pregnant women hospitalized for obstetric reasons,³³ and COVID-19 infection has been associated with preterm birth and severe maternal health complications.³⁴ Asthma and respiratory infections during pregnancy may also be linked to risks of adverse birth outcomes.^{35;36} Prepregnancy obesity may be associated with infants being born large for their gestational age,³⁷ and to abnormal brain development.³⁸

Kaiser Permanente research has linked maternal vitamin D insufficiency with risks for child asthma³⁹ and allergic sensitization,⁴⁰ and it is unclear that prenatal vitamin D supplementation mitigates these risks.⁴¹ Our scientists have found that poor diet and a variety of pregnancy complications, including preterm delivery, preeclampsia, and macrosomia, are associated with gestational weight gain that is greater than recommended.⁴²⁻⁴⁸ Conversely, recent research has confirmed that a healthy prepregnancy weight, a high-quality diet, and low-to-moderate personal stress are protective against the risk of preterm birth.⁴⁹

Kaiser Permanente scientists have explored the role of behavioral health conditions on pregnancy outcomes. Women who develop symptoms of depression early in their pregnancies may have poorer diets⁵⁰ and may gain more weight,⁵¹ and the risk of preterm delivery is significantly higher in women with depression.⁵² Unplanned pregnancies have been shown to be more common among women who have undergone adverse childhood experiences, such as neglect or the loss of a parent,⁵³ and these pregnancies are associated with a variety of adverse outcomes for both mothers and newborns.⁵⁴ Although recent data suggest that prenatal use of alcohol and tobacco products is decreasing,⁵⁵ addictive substances are associated with significant risks.⁵⁶ Preterm delivery and low birth weight have also been linked to use of benzodiazepines during pregnancy,⁵⁷ and alcohol use during pregnancy has been associated with the risk of miscarriage.⁵⁸ Although the risks associated with cannabis use during pregnancy are unclear, pregnant women appear to be increasing their use of cannabis,⁵⁹⁻⁶¹ particularly during the COVID-19 pandemic,⁶² and increasingly doing so in conjunction with alcohol and stimulants.⁶³ Other research has found that pregnant women who consume cannabis do so most often via smoking,⁶⁴ that these women use cannabis more frequently if they have mental health diagnoses,⁶⁵ and that use of cannabis is often associated with use of psychoactive medications (such as benzodiazepines and hypnotics) that may increase risks for poor birth outcomes.⁶⁶

Scientists at Kaiser Permanente have also studied the risks associated with induced or cesarean deliveries. Use of cesarean delivery has increased over time,⁶⁷ and these procedures are not without postpartum risks for the mother.⁶⁸ Studies conducted by our scientists have also found that infants born via cesarean took longer to regain their birth weight during the first month of life.⁶⁹ Of particular concern is evidence that the decision to use cesarean delivery is sometimes driven by nonmedical factors rather than medical necessity.⁷⁰ Elective induction of labor may be associated with lower odds of cesarean delivery,⁷¹ although its safety remains to be clearly established.⁷¹⁻⁷⁴

What issues arise with respect to the safety of routine care for pregnant women?

As an integrated care organization, Kaiser Permanente actively works to ensure that routine medical care is maintained throughout a woman's pregnancy. While many elements of routine care can be maintained safely during pregnancy, basic data regarding the safety of medications during pregnancy are often lacking.^{75,76} Our scientists have been involved in research examining the safety of medications in wide use among pregnant women, such as antidepressants,⁷⁷⁻⁸⁰ nonsteroidal anti-inflammatory drugs,⁸¹ beta blockers,^{82,83} ACE inhibitors,²⁹ other anti-hypertensive drugs,⁸³ sulfonamide antibiotics,⁸⁴ and biologic medications.⁸⁵⁻⁸⁸ Kaiser Permanente has also been involved in numerous studies of the prevalence of medication use during pregnancy. Two of these studies showed rapid increases in the use of atypical antipsychotics and antiepileptic drugs among pregnant women in recent years, despite limited information on the safety of these medications.^{89,90} Studies such as these can lead to future research with the potential to improve the safety of medications prescribed during pregnancy. Researchers at Kaiser Permanente have also studied the safety of vaccines in pregnant women.⁹¹⁻⁹⁵ A series of studies conducted through the Vaccine Safety Datalink project⁹⁶ found no increased risk of adverse birth outcomes in women receiving immunizations for flu,⁹⁷⁻¹⁰¹ tetanus-diphtheria-pertussis (Tdap),¹⁰⁰⁻¹⁰⁵ pertussis alone,¹⁰⁶ hepatitis

Kaiser Permanente research is helping to address the lack of research on the safety of common medications in pregnancy.

In over 375,000 pregnancies, maternal use of the beta-blockers metoprolol and propranolol was not associated with higher risks of infants being born small for gestational age.⁸²



A study of angiotensin-converting enzyme inhibitor (ACEI) safety in over 460,000 pregnancies found that the risk of congenital malformations arises from underlying hypertension rather than the use of ACEIs.²⁹



In an analysis involving 1.2 million pregnancies, the use of sulfonamide antibiotics was not associated with the risk of congenital malformations.⁸⁴



B,¹⁰⁷ human papillomavirus (HPV),¹⁰⁸⁻¹¹⁰ or COVID-19.¹¹¹⁻¹¹³

Are there subgroups of mothers and/or newborn children who are at particularly high risk for these health problems?

Our scientists have studied subpopulations of mothers and newborns for whom health risks are heightened. Women with ongoing comorbid conditions may experience adverse outcomes if these conditions are not managed effectively during pregnancy.¹¹⁴ Complications such as gestational diabetes mellitus or preeclampsia that occur during one pregnancy are likely to recur in future pregnancies,^{115;116} and weight gain between pregnancies may increase the risk of GDM¹¹⁷ and preeclampsia¹¹⁸ in subsequent pregnancies. Our research has also found that

a stillbirth is associated with increased risks of future adverse outcomes, including infant mortality.¹¹⁹

Racial, ethnic, socioeconomic,¹²⁰ and social factors¹²¹ are also associated with increased risk for health problems during and after pregnancy. Our scientists have identified elevated risks of gestational diabetes in Asian American¹²²⁻¹²⁵ and Black^{123;126} women, and in women born outside the United States,¹²⁷ and preeclampsia,¹²⁸ infertility,¹²⁹ diabetes,¹³⁰ and higher-weight infants^{131;132} have been found to be more common in Black women. Our research has also confirmed that poor nutrition during pregnancy – common among people of lower socioeconomic status¹³³ – is associated with poor birth outcomes^{134;135} and ongoing health problems including insulin resistance¹³⁶ and weight gain.¹³⁷ Asian American women are also more likely than White women to deliver via cesarean procedure, and to experience preterm birth, and recent work has found that these disparities cannot be explained by maternal cardiometabolic health.^{138;139} Exposure to poor air quality and environmental toxins has been linked to increased risks of gestational diabetes, preterm births, and low birth weight births, with Black mothers at particularly high risk.¹⁴⁰⁻¹⁴³ A study conducted among Kaiser Permanente members found that higher psychosocial stress was associated with greater gestational weight gain,¹⁴⁴ and women with greater levels of conflict with their partners may be at greater risk of postpartum depression.¹⁴⁵ More recently, disruptions in access to prenatal care during the COVID-19 pandemic have been associated with greater prenatal depression and anxiety among Black and Latina women.¹⁴⁶

What are the health consequences of the risks that mothers and newborn children face?

Kaiser Permanente scientists have studied a variety of factors associated with significant health risks during pregnancy. Health conditions that mothers experience during pregnancy may also increase their risks for longer-term chronic diseases, including obesity,¹⁴⁷⁻¹⁴⁹ diabetes,¹⁵⁰⁻¹⁵³ hypertension,¹⁵⁴⁻¹⁵⁷ cardiovascular disease,¹⁵⁸⁻¹⁶⁰

nonalcoholic liver disease,¹⁶¹ chronic kidney disease,¹⁶² and even ophthalmic disorders.¹⁶³ In particular, health issues requiring treatment and monitoring, such as depression, gestational diabetes, or hypertension, may go untreated if the mother's primary care physician is not involved in her postdelivery care,^{164;165} or if she is not referred for needed mental health services.¹⁶⁶⁻¹⁶⁸ One recent study found that self-harming behaviors may be a significant contributor to maternal mortality.¹⁶⁹

Maternal diabetes has been linked to neonatal deaths,¹⁷⁰ and children born to mothers with prepregnancy obesity, greater gestational weight gain, hyperglycemia, or GDM may also experience longer-term health problems including obesity^{20;171-183} and asthma.^{184;185} Additional long-term risks to newborns that may arise from conditions in pregnancy include metabolic illnesses,¹⁸⁶⁻¹⁸⁸ childhood asthma,^{189;190} autism,¹⁹¹⁻¹⁹³ attention deficit hyperactivity disorders,^{194;195} developmental delay,¹⁹² cerebral palsy, and other congenital defects.¹⁹⁶⁻¹⁹⁸ Our scientists have studied a variety of factors associated with greater risk of autism,¹⁹¹ including toxic exposures,¹⁹⁹⁻²⁰⁵ inflammatory conditions,²⁰⁶⁻²⁰⁹ maternal fever²¹⁰ or infection,^{211;212} gestational weight gain,¹⁹² gestational diabetes,^{213;214} and preterm birth.²¹⁵ Use of opioids during pregnancy has been shown to increase the risk of neurodevelopmental problems, including autism spectrum disorder and developmental delay.²¹⁶ Fetal alcohol syndrome²¹⁷ and autism spectrum disorder²¹⁸ are among the risks of drinking alcohol while pregnant. Preterm delivery,¹⁹⁸ maternal fever,²¹⁰ and prepregnancy obesity¹⁹² have also been found by Kaiser Permanente research to be linked to the risk of developmental delay. One study of preterm and very low birth weight infants found that they often experience significantly reduced quality of life in young adulthood,²¹⁹ and preterm birth is associated with increased social isolation and financial stress on the child's family,²²⁰ as well as an elevated risk of developing type 2 diabetes.²²¹

Improving Patient Outcomes

What prevention or early intervention strategies can mitigate the health risks faced by mothers and newborn children?

Prevention and other early intervention strategies are critical components of Kaiser Permanente's work to improve pregnancy outcomes. Engaging women in birth planning^{222;223} and early prenatal care²²³⁻²²⁶ have been shown to contribute to superior outcomes. Other programs evaluated in Kaiser Permanente encourage natural vaginal delivery as a way of preventing unnecessary cesarean births,^{227;228} as natural delivery is associated with fewer risks and shorter recovery times.^{69;229} Our research has consistently suggested that breastfeeding may reduce the risk of childhood obesity^{175;230-233} and other unfavorable outcomes,²³⁴ and we have evaluated a variety of programs for encouraging breastfeeding among new mothers.^{235;236} Kaiser Permanente scientists were also involved in a randomized trial demonstrating shorter hospital stays, superior rates of breastfeeding, and higher patient satisfaction associated with an evidence-based enhanced recovery program after cesarean delivery.²³⁷

Screening programs are an integral piece of our organization's approach to preventive health, and our researchers have studied efforts to screen pregnant women for peripartum and postpartum depression,²³⁸⁻²⁴⁰ preeclampsia,^{241;242} and gestational diabetes.²⁴³⁻²⁴⁶ Our scientists have conducted comparisons of the 1-step GDM screening protocol recommended by the International Association of Diabetes and Pregnancy Study Groups versus standard 2-step screening, and have found that 1-step screening does not lead to improved maternal or neonatal outcomes.²⁴⁷⁻²⁴⁹ Our scientists have also studied postpartum screening efforts to identify diabetes following pregnancies affected by GDM.²⁵⁰⁻²⁵² Other strategies that contribute to improved outcomes for mothers and babies include management of weight²⁵³⁻²⁵⁹ and nutrition,^{134;135;260;261} and provision of specialized care and outreach for high-risk

Kaiser Permanente has studied the effectiveness of early intervention efforts to improve pregnancy outcomes.



Birth planning^{222;223}



Early prenatal care²²³⁻²²⁶



Weight management²⁵³⁻²⁵⁷



Nutrition^{134;135;260;261}



Specialized care for high-risk pregnancies^{240;262;263}



Postpartum depression prevention²⁷²



Screening for:

- **Preeclampsia**^{241;242}
- **Gestational diabetes**²⁴³⁻²⁴⁵
- **Postpartum depression**²³⁸⁻²⁴⁰

pregnancies.^{240;262;263} In addition, our scientists have studied screening and brief intervention efforts for alcohol use during pregnancy,²⁶⁴⁻²⁶⁸ as well as counseling and other programs aimed at promoting cessation of tobacco²⁶⁹ and alcohol²⁷⁰ use in pregnant women.

Strategies to prevent and mitigate postpartum risks are also a focus of Kaiser Permanente's research. In light of evidence that care for postpartum depression has not improved despite provisions of the Affordable Care Act,²⁷¹ we have studied various prevention strategies, including mindfulness-based cognitive behavioral therapy,²⁷² as well as

behavioral activation²⁷³ and collaborative care²⁷⁴ for depression during pregnancy. In a randomized trial comparing various programs for postpartum weight control, a lifestyle intervention based on the Diabetes Prevention Program improved physical activity and weight maintenance.^{255;275} Our scientists have also studied a variety of interventions to address new parents' hesitancy regarding vaccinations for newborns.²⁷⁶⁻²⁸¹

What are the key components of approaches to reduce disparities in care and outcomes experienced by mothers and newborn children?

As part of Kaiser Permanente's commitment to reducing disparities in access to care and clinical outcomes, we have studied the experiences of women and newborn children at increased risk of poor outcomes. Our research has found that cesarean deliveries are more common in Black women,⁶⁷ and access to recommended care for postpartum depression among Medicaid enrollees was lower for Black women and Latinas than for White women.²⁸² Moreover, infants with similar respiratory symptoms may receive different treatments depending on their race or ethnicity.²⁸³ As part of a strategy to address these and other disparities, researchers at Kaiser Permanente have studied interventions to increase the cultural competence of care provided during and after pregnancy.²⁸⁴

Translating Research Findings Into Policy and Practice

Kaiser Permanente is a learning health care organization that works to systematically use research to inform and improve practice. Research, clinical, and operational partners within Kaiser Permanente have tested a range of interventions to reduce the risk of poor maternal and child health outcomes, both during and following pregnancy. Our scientists are involved in a perinatal care center managed by nurse-midwives in which cesarean section is used in just 10% of deliveries, and nearly all mothers are engaged in breastfeeding.²⁸⁵ Kaiser Permanente clinicians returned to a 2-step strategy for GDM

Two studies conducted in Kaiser Permanente members found that 1-step screening for gestational diabetes was associated with more GDM diagnoses, but not better outcomes.^{247;248}

Southern California		Washington State	
1-step	2-step	1-step	2-step
Pregnancies			
3,094 2011-2013	2,972 2010-2011	6,337 2012-2014	4,977 2009-2011
GDM diagnoses			
27%	17%	11%	7%
Large for gestational age births			
9%	10%	10%	10%
Neonatal macrosomia			
7%	8%	2%	3%

screening after experimenting with a 1-step strategy, after 2 studies conducted by our researchers found that 1-step screening was associated with increased rates of GDM diagnoses without improved outcomes.^{247;248} Based on research demonstrating that the 1979 National Diabetes Data Group glucose threshold for diagnosing GDM was associated with greater newborn health risks than the lower American Diabetes Association (ADA) threshold published in 2000, the ADA threshold was implemented throughout Kaiser Permanente.²¹ Our organization's electronic health record system was used to implement a new standard for diagnosing maternal hypertension, leading to improvements in identifying women who may develop preeclampsia, as well as fetuses and neonates at high risk of adverse birth outcomes.²⁸⁶ Finally, based on randomized trials conducted by our scientists, we have successfully translated interventions into practice for preventing postpartum depression,²⁷² improving gestational weight gain,^{258;287;288} and increasing vaccination uptake.^{276;278;289}

Kaiser Permanente research contributes not only to policy and practice change within our own care delivery organization, but has also advanced national understanding of maternal and child health. To date, Kaiser Permanente's research on maternal and child health since 2007 has been cited more than 530 times within recent consensus statements and clinical practice guidelines published by a wide range of entities, including the CDC's Advisory Committee on Immunization Practices,^{290;291} the American Academy of Pediatrics,²⁹² and the American College of Obstetricians and Gynecologists.²⁹³ In addition, Kaiser Permanente researchers and clinician-scientists have directly contributed as authors of guidelines and policy statements for the Society for Obstetric Anesthesia and Perinatology,²⁹⁴ the American Heart Association,²⁹⁵ and the U.S. Preventive Services Task Force.^{236;241;242;244;269;296-301} Our scientists have also contributed to a consensus bundle developed for the National Partnership for Maternal Safety, which addresses recommended clinical practices for recognizing and responding to venous thromboembolisms in obstetric patients,³⁰² and a practice resource for prenatal and preconception genetic screening developed for the American College of Medical Genetics and Genomics.³⁰³ Finally, Kaiser Permanente researchers participated in a workshop regarding research gaps in gestational diabetes, sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases.³⁰⁴

Kaiser Permanente has shown leadership in the broader field of maternal and child health research. Our scientists are leaders in a number of prominent studies in this field, including the Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) study, an effort to explore the in utero safety of medications delivered to pregnant women.^{75;305} We are also involved in ongoing efforts to study the effectiveness and safety of vaccines delivered to mothers and infants as part of our involvement in the Vaccine Safety Datalink, a nationwide project sponsored by the CDC,^{306;307} as well as conducting research on the effectiveness of COVID-19 vaccination in pregnant women.^{308;309} Kaiser Permanente is conducting long-term research on 2 groups of women and children as part of the Environmental influences on Child Health Outcomes program.³¹⁰

Kaiser Permanente's 185 research scientists and 1,530 support staff members are based at 9 research centers. There are currently 2,355 studies underway, including clinical trials. Since 2007 our research scientists have published nearly 23,000 articles in peer-reviewed journals. Kaiser Permanente currently serves approximately 12.6 million members in 8 states and the District of Columbia.

This brief was written by Nicholas P. Emptage, Anna C. Davis, and Elizabeth A. McGlynn. It is available online from about.kaiserpermanente.org/our-story/health-research/research-briefs. The authors wish to thank the following researchers for their contributions to the development of this brief: Sascha Dublin, Assiamira Ferrara, and Darios T. Getahun.

References

1. Hamilton BE, Martin JA, Osterman MJK. *Births: Provisional Data for 2021*. Hyattsville, MD: Centers for Disease Control, National Center for Health Statistics, National Vital Statistics System;2022.
2. Zong X, Wang H, Yang L, et al. Maternal Pre-pregnancy Body Mass Index Categories and Infant Birth Outcomes: A Population-Based Study of 9 Million Mother-Infant Pairs. *Front Nutr*. 2022;9:789833.
3. Centers for Disease Control and Prevention. Diabetes During Pregnancy. 2018; <https://www.cdc.gov/reproductivehealth/maternalinfanthealth/diabetes-during-pregnancy.htm>. Accessed June 21, 2023.
4. Ford ND, Cox S, Ko JY, et al. Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization - United States, 2017-2019. *MMWR Morb Mortal Wkly Rep*. 2022;71(17):585-591.
5. Martin JA, Osterman MJK, Driscoll AK. Declines in Cigarette Smoking During Pregnancy in the United States, 2016-2021. *NCHS Data Brief*. 2023(458):1-8.
6. Substance Abuse and Mental Health Services Administration CbBHSaQ. 2021 National Survey on Drug Use and Health. Table 8.25B—Types of illicit drug, tobacco product, and alcohol use in past month: among females aged 15 to 44; by pregnancy status, percentages, 2021. 2023; <https://www.samhsa.gov/data/sites/default/files/reports/rpt39441/NSDUHDetailedTabs2021/NSDUHDetailedTabs2021/NSDUHDetTabsSect8pe2021.htm#tab8.25b>. Accessed June 21, 2023.
7. Center for Behavioral Health Statistics and Quality. *2017 National Survey on Drug Use and Health*. Rockville, MD: Substance Abuse and Mental Health Services Administration;2018.
8. Centers for Disease Control and Prevention. Gestational Diabetes. 2022; <https://www.cdc.gov/diabetes/basics/gestational.html>. Accessed August 23, 2019.
9. Centers for Disease Control and Prevention. Pregnancy Mortality Surveillance System. *Maternal and Infant Health 2023*; <https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.htm>. Accessed August 16, 2023.
10. Centers for Disease Control and Prevention. Preterm Birth. 2022; <https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm>. Accessed June 21, 2023.
11. Centers for Disease Control and Prevention. FastStats - Birthweight. 2023; <https://www.cdc.gov/nchs/fastats/birthweight.htm>. Accessed June 21, 2023.
12. KPPL Search conducted on June 15, 2023: (((Msubject:Maternal Health) OR (Msubject:Maternal Welfare) OR (Msubject: prenatal care) OR Msubject:Pregnancy OR (Msubject:Pregnancy Complications) OR (Msubject:Hypertension, Pregnancy-Induced) OR Msubject:Eclampsia OR (Msubject:Pre-Eclampsia) OR (Msubject:Maternal Death) OR Msubject:Gravidity OR (Msubject:Labor, Obstetric) OR Msubject:Parity OR (Msubject:Uterine Contraction) OR (Msubject:Diabetes, Gestational) OR (Msubject:Fetal Macrosomia) OR (Msubject:Fetal death) OR Msubject:stillbirth OR (Msubject:Fetal Diseases) OR Msubject:Chorioamnionitis OR (Msubject:Fetal Alcohol Spectrum Disorders) OR (Msubject:Fetal Growth Retardation) OR (Msubject:Fetal Hypoxia) OR (Msubject:Fetal Nutrition Disorders) OR (Msubject:Amniotic Fluid) OR (Msubject:Fetal Blood) OR (Msubject:Fetal heart) OR Msubject:fetus OR (Msubject:Umbilical Cord) OR (Msubject:Umbilical Arteries) OR Msubject:Abortion OR (Msubject:Obstetric Labor Complications) OR (Msubject:Depression, Postpartum) OR (Msubject:Postpartum Period) OR (Msubject:peripartum Period) OR (Msubject:postnatal care) OR (Msubject:Birth Weight) OR (Msubject:premature Birth) OR (Msubject:Pregnancy Outcome) OR (Msubject:Cesarean Section) OR (Msubject:Anemia, Neonatal) OR Msubject:colic OR Msubject:Hydrophthalmos OR (Msubject:Hyperbilirubinemia, Neonatal) OR (Msubject:Jaundice, Neonatal) OR (Msubject:Bronchopulmonary Dysplasia) OR (Msubject:Respiratory Distress Syndrome, Newborn) OR (Msubject:Neonatal Abstinence Syndrome) OR (Msubject:Neonatal Sepsis) OR Msubject:Nurseries OR (Msubject:Persistent Fetal Circulation Syndrome) OR (Msubject:Syphilis, Congenital) OR Msubject:Parturition OR (Msubject:Breast Feeding) OR (Msubject:Prenatal Nutritional Physiological Phenomena) OR (Msubject:Bottle Feeding) OR (Msubject:Vaginal Birth after Cesarean) OR (Msubject:Delivery, Obstetric) OR (Msubject:Cesarean Section) OR Msubject:Episiotomy OR (Msubject:Extraction, Obstetrical) OR (Msubject:Labor, Induced) OR Msubject:Puerperal OR (Msubject: prenatal diagnosis) OR (Msubject:Genetic Diseases, Inborn) OR (Msubject:neonatal screening) OR (Msubject:Maternal Serum Screening Tests) OR (Msubject:Ultrasonography, Prenatal) OR (Msubject:Prenatal Exposure Delayed Effects) OR (Msubject:Maternal Exposure) OR (Msubject:infant NOT (Msubject:child OR Msubject:adolescent)) OR (title:newborn* OR title:fetus OR title:foetus OR title:Periconceptional OR (title:maternal exposure~6) OR (title:In-utero exposure~6) OR (title:Birth Weight~6) OR (title:Premature birth) OR (title:Preterm birth) OR (title:Early development) OR title:Prepregnant OR title:Birthweight OR title:Gestation OR title:Breastfeeding OR (title:breast milk) OR title:pregnan*) AND type:journal article AND datelssued:[2007 2023].
13. Hedderson MM, Williams MA, Holt VL, et al. Body mass index and weight gain prior to pregnancy and risk of gestational diabetes mellitus. *Am J Obstet Gynecol*. 2008;198(4):409.e401-407.
14. Hedderson MM, Gunderson EP, Ferrara A. Gestational weight gain and risk of gestational diabetes mellitus. *Obstet Gynecol*. 2010;115(3):597-604.
15. Zhu Y, Hedderson MM, Quesenberry CP, et al. Central Obesity Increases the Risk of Gestational Diabetes Partially Through Increasing Insulin Resistance. *Obesity (Silver Spring)*. 2019;27(1):152-160.

16. Hedderson MM, Ferrara A. High blood pressure before and during early pregnancy is associated with an increased risk of gestational diabetes mellitus. *Diabetes Care*. 2008;31(12):2362-2367.
17. Chen L, Pocobelli G, Yu O, et al. Early Pregnancy Hemoglobin A1C and Pregnancy Outcomes: A Population-Based Study. *Am J Perinatol*. 2019;36(10):1045-1053.
18. Francis EC, Li M, Hinkle SN, et al. Adipokines in early and mid-pregnancy and subsequent risk of gestational diabetes: a longitudinal study in a multiracial cohort. *BMJ Open Diabetes Res Care*. 2020;8(1):e001333.
19. Sarkar M, Grab J, Dodge JL, et al. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. *J Hepatol*. 2020;73(3):516-522.
20. Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. *Nat Rev Endocrinol*. 2012;8(11):639-649.
21. Ferrara A, Weiss NS, Hedderson MM, et al. Pregnancy plasma glucose levels exceeding the American Diabetes Association thresholds, but below the National Diabetes Data Group thresholds for gestational diabetes mellitus, are related to the risk of neonatal macrosomia, hypoglycaemia and hyperbilirubinaemia. *Diabetologia*. 2007;50(2):298-306.
22. Sacks DA. Etiology, detection, and management of fetal macrosomia in pregnancies complicated by diabetes mellitus. *Clin Obstet Gynecol*. 2007;50(4):980-989.
23. Hapo Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med*. 2008;358(19):1991-2002.
24. Lowe WL, Scholtens DM, Kuang A, et al. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Gestational Diabetes and Childhood Glucose Metabolism. *Diabetes Care*. 2019;42(3):372-380.
25. Scholtens DM, Kuang A, Lowe LP, et al. Hyperglycemia and Adverse Pregnancy Outcome Follow-Up Study (HAPO FUS): Maternal Glycemia and Childhood Glucose Metabolism. *Diabetes Care*. 2019;42(3):381-392.
26. Martinez MP, Lin J, Chow T, et al. Maternal Gestational Diabetes and Type 2 Diabetes During Pregnancy and Risk of Childhood Asthma in Offspring. *J Pediatr*. 2020;219:173-179.e171.
27. Gunderson EP, Sun B, Catov JM, et al. Gestational Diabetes History and Glucose Tolerance After Pregnancy Associated With Coronary Artery Calcium in Women During Midlife: The CARDIA Study. *Circulation*. 2021;143(10):974-987.
28. Perak AM, Lancki N, Kuang A, et al. Associations of Maternal Cardiovascular Health in Pregnancy With Offspring Cardiovascular Health in Early Adolescence. *JAMA*. 2021;325(7):658-668.
29. Li DK, Yang C, Andrade S, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. *BMJ*. 2011;343:d5931.
30. Hedderson MM, Darbinian JA, Sridhar SB, Quesenberry CP. Prepregnancy cardiometabolic and inflammatory risk factors and subsequent risk of hypertensive disorders of pregnancy. *Am J Obstet Gynecol*. 2012;207(1):68.e61-69.
31. Black MH, Zhou H, Sacks DA, et al. Prehypertension prior to or during early pregnancy is associated with increased risk for hypertensive disorders in pregnancy and gestational diabetes. *J Hypertens*. 2015;33(9):1860-1867.
32. Mirzakhani H, Carey VJ, McElrath TF, et al. The Association of Maternal Asthma and Early Pregnancy Vitamin D with Risk of Preeclampsia: An Observation From Vitamin D Antenatal Asthma Reduction Trial (VDAART). *J Allergy Clin Immunol Pract*. 2018;6(2):600-608.e602.
33. Panagiotakopoulos L, Myers TR, Gee J, et al. SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(38):1355-1359.
34. Ferrara A, Hedderson MM, Zhu Y, et al. Perinatal Complications in Individuals in California With or Without SARS-CoV-2 Infection During Pregnancy. *JAMA Intern Med*. 2022;182(5):503-512.
35. Regan AK, Feldman B, Azziz-Baumgartner E, et al. An international cohort study of birth outcomes associated with hospitalized acute respiratory infection during pregnancy. *J Infect*. 2020;81(1):48-56.
36. Yland JJ, Bateman BT, Huybrechts KF, et al. Perinatal Outcomes Associated with Maternal Asthma and its Severity and Control during Pregnancy. *J Allergy Clin Immunol Pract*. 2020;8(6):1928-1937.e1923.
37. Black MH, Sacks DA, Xiang AH, Lawrence JM. The relative contribution of prepregnancy overweight and obesity, gestational weight gain, and IADPSG-defined gestational diabetes mellitus to fetal overgrowth. *Diabetes Care*. 2013;36(1):56-62.
38. Alves JM, Luo S, Chow T, et al. Sex differences in the association between prenatal exposure to maternal obesity and hippocampal volume in children. *Brain Behav*. 2020;10(2):e01522.
39. Lu M, Litonjua AA, O'Connor GT, et al. Effect of early and late prenatal vitamin D and maternal asthma status on offspring asthma or recurrent wheeze. *J Allergy Clin Immunol*. 2021;147(4):1234-1241.e1233.
40. Chen YS, Mirzakhani H, Lu M, et al. The association of prenatal vitamin D sufficiency with aeroallergen sensitization and allergic rhinitis in early childhood. *J Allergy Clin Immunol Pract*. 2021;9(10):3788-3796.e3783.

41. Litonjua AA, Carey VJ, Laranjo N, et al. Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. *N Engl J Med*. 2020;382(6):525-533.
42. Chu SY, Bachman DJ, Callaghan WM, et al. Association between obesity during pregnancy and increased use of health care. *N Engl J Med*. 2008;358(14):1444-1453.
43. Goldstein RF, Abell SK, Ranasinha S, et al. Association of Gestational Weight Gain With Maternal and Infant Outcomes: A Systematic Review and Meta-analysis. *JAMA*. 2017;317(21):2207-2225.
44. Kim SS, Mendola P, Zhu Y, et al. Spontaneous and indicated preterm delivery risk is increased among overweight and obese women without prepregnancy chronic disease. *BJOG*. 2017;124(11):1708-1716.
45. Hillier TA, Pedula KL, Vesco KK, et al. Excess gestational weight gain: modifying fetal macrosomia risk associated with maternal glucose. *Obstet Gynecol*. 2008;112(5):1007-1014.
46. Goldstein RF, Abell SK, Ranasinha S, et al. Gestational weight gain across continents and ethnicity: systematic review and meta-analysis of maternal and infant outcomes in more than one million women. *BMC Med*. 2018;16(1):153.
47. Badon SE, Dublin S, Nance N, et al. Gestational weight gain and adverse pregnancy outcomes by pre-pregnancy BMI category in women with chronic hypertension: A cohort study. *Pregnancy Hypertens*. 2020;23:27-33.
48. Liu EF, Zhu Y, Ferrara A, Hedderson MM. Dietary Quality Indices in Early Pregnancy and Rate of Gestational Weight Gain among a Prospective Multi-Racial and Ethnic Cohort. *Nutrients*. 2023;15(4):02.
49. Zhu Y, Hedderson MM, Brown SD, et al. Healthy preconception and early-pregnancy lifestyle and risk of preterm birth: a prospective cohort study. *Am J Clin Nutr*. 2021;114(2):813-821.
50. Avalos LA, Caan B, Nance N, et al. Prenatal Depression and Diet Quality During Pregnancy. *J Acad Nutr Diet*. 2020;120(6):972-984.
51. Badon SE, Hedderson MM, Hyde RJ, et al. Pre- and Early Pregnancy Onset Depression and Subsequent Rate of Gestational Weight Gain. *J Womens Health (Larchmt)*. 2019;28(9):1237-1245.
52. Li D, Liu L, Odouli R. Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. *Hum Reprod*. 2009;24(1):146-153.
53. Young-Wolff KC, Wei J, Varnado N, et al. Adverse Childhood Experiences and Pregnancy Intentions among Pregnant Women Seeking Prenatal Care. *Womens Health Issues*. 2021;31(2):100-106.
54. Nelson HD, Darney BG, Ahrens K, et al. Associations of Unintended Pregnancy With Maternal and Infant Health Outcomes: A Systematic Review and Meta-analysis. *JAMA*. 2022;328(17):1714-1729.
55. Young-Wolff KC, Sarovar V, Alexeeff SE, et al. Trends and correlates of self-reported alcohol and nicotine use among women before and during pregnancy, 2009-2017. *Drug Alcohol Depend*. 2020;214:108168.
56. Pocobelli G, Dublin S, Bobb JF, et al. Prevalence of prescription opioid use during pregnancy in 8 U.S. health plans during 2001-2014. *Pharmacoepidemiol Drug Saf*. 2021;30(11):1541-1550.
57. Shyken JM, Babbar S, Babbar S, Forinash A. Benzodiazepines in Pregnancy. *Clin Obstet Gynecol*. 2019;62(1):156-167.
58. Avalos LA, Roberts SC, Kaskutas LA, et al. Volume and Type of Alcohol During Early Pregnancy and the Risk of Miscarriage. *Subst Use Misuse*. 2014;49(11):1437-1445.
59. Young-Wolff KC, Sarovar V, Tucker LY, et al. Trends in marijuana use among pregnant women with and without nausea and vomiting in pregnancy, 2009-2016. *Drug Alcohol Depend*. 2019;196:66-70.
60. Young-Wolff KC, Sarovar V, Tucker LY, et al. Self-reported daily, weekly, and monthly cannabis use among women before and during pregnancy. *JAMA Network Open*. 2019;2(7):e196471.
61. Goler N, Conway A, Young-Wolff KC. Data Are Needed on the Potential Adverse Effects of Marijuana Use in Pregnancy. *Ann Intern Med*. 2018;169(7):492-493.
62. Young-Wolff KC, Ray GT, Alexeeff SE, et al. Rates of Prenatal Cannabis Use Among Pregnant Women Before and During the COVID-19 Pandemic. *JAMA*. 2021;326(17):1745-1747.
63. Young-Wolff KC, Sarovar V, Tucker LY, et al. Trends in Cannabis Polysubstance Use During Early Pregnancy Among Patients in a Large Health Care System in Northern California. *JAMA Netw Open*. 2022;5(6):e2215418.
64. Young-Wolff KC, Adams SR, Wi S, et al. Routes of cannabis administration among females in the year before and during pregnancy: Results from a pilot project. *Addict Behav*. 2019;100:106125.
65. Young-Wolff KC, Sarovar V, Tucker LY, et al. Association of Depression, Anxiety, and Trauma With Cannabis Use During Pregnancy. *JAMA Netw Open*. 2020;3(2):e1921333.
66. Hirschtritt ME, Avalos LA, Sarovar V, et al. Association Between Prenatal Cannabis Use and Psychotropic Medication Use in Pregnant Patients With Depression and Anxiety. *J Addict Med*. 2022;16(4):e269-e273.
67. Getahun D, Strickland D, Lawrence JM, et al. Racial and ethnic disparities in the trends in primary cesarean delivery based on indications. *Am J Obstet Gynecol*. 2009;201(4):422.e421-427.
68. Butwick AJ, Walsh EM, Kuzniewicz M, et al. Patterns and predictors of severe postpartum anemia after Cesarean section. *Transfusion*. 2017;57(1):36-44.

69. Paul IM, Schaefer EW, Miller JR, et al. Weight Change Nomograms for the First Month After Birth. *Pediatrics*. 2016;138(6):11.
70. Hessel NA, Odouli R, Escobar GJ, et al. Interpersonal Processes of Care and Cesarean Delivery in Two Health Care Settings. *Am J Public Health*. 2012;102(9):1722-1728.
71. Darney BG, Snowden JM, Cheng YW, et al. Elective induction of labor at term compared with expectant management: maternal and neonatal outcomes. *Obstet Gynecol*. 2013;122(4):761-769.
72. Snowden JM, Muoto I, Darney BG, et al. Oregon's Hard-Stop Policy Limiting Elective Early-Term Deliveries: Association With Obstetric Procedure Use and Health Outcomes. *Obstet Gynecol*. 2016;128(6):1389-1396.
73. Muoto I, Darney BG, Lau B, et al. Shifting Patterns in Cesarean Delivery Scheduling and Timing in Oregon before and after a Statewide Hard Stop Policy. *Health Serv Res*. 2018;53 Suppl 1:2839-2857.
74. Getahun D. Epidemiologic Considerations: Scope of Problem and Disparity Concerns. *Clin Obstet Gynecol*. 2014;57(2):326-330.
75. Davis RL. Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP). *J Popul Ther Clin Pharmacol*. 2010;17(3):e336-340.
76. Dublin S, Wartko P, Mangione-Smith R. Studying Medication Safety in Pregnancy: A Call for New Approaches, Resources, and Collaborations. *Pediatrics*. 2020;146(1):e20201540.
77. Wartko PD, Weiss NS, Enquobahrie DA, et al. Association of Antidepressant Continuation in Pregnancy and Infant Birth Weight. *J Clin Psychopharmacol*. 2021;41(4):403-413.
78. Ames JL, Ladd-Acosta C, Fallin MD, et al. Maternal Psychiatric Conditions, Treatment With Selective Serotonin Reuptake Inhibitors, and Neurodevelopmental Disorders. *Biol Psychiatry*. 2021;90(4):253-262.
79. Wiggs KK, Suján AC, Rickert ME, et al. Maternal Serotonergic Antidepressant Use in Pregnancy and Risk of Seizures in Children. *Neurology*. 2022;98(23):e2329-e2336.
80. Nance N, Badon SE, Ridout K, et al. Associations between antidepressant use patterns during pregnancy and birth outcomes among periconception antidepressant users. *Pharmacotherapy*. 2023;43(5):372-380.
81. Li DK, Ferber JR, Odouli R, Quesenberry C. Use of non-steroidal anti-inflammatory drugs during pregnancy and the risk of miscarriage. *Am J Obstet Gynecol*. 2018;219(3):275.e271-275.e278.
82. Duan L, Ng A, Chen W, et al. Beta-blocker subtypes and risk of low birth weight in newborns. *J Clin Hypertens (Greenwich)*. 2018;20(11):1603-1609.
83. Dublin S, Idu A, Avalos LA, et al. Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: A retrospective cohort study. *PLoS ONE*. 2022;17(5):e0268284.
84. Hansen C, Andrade SE, Freiman H, et al. Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies. *Pharmacoepidemiol Drug Saf*. 2016;25(2):170-178.
85. Mahadevan U, Long MD, Kane SV, et al. Pregnancy and Neonatal Outcomes after Fetal Exposure To Biologics and Thiopurines among Women with Inflammatory Bowel Disease. *Gastroenterology*. 2021;160(4):1131-1139.
86. Smith JB, Hellwig K, Fink K, et al. Rituximab, MS, and pregnancy. *Neurol Neuroimmunol Neuroinflamm*. 2020;7(4):05.
87. Ciplea AI, Langer-Gould A, de Vries A, et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. *Neurol Neuroimmunol Neuroinflamm*. 2020;7(4):04.
88. Hellwig K, Tokic M, Thiel S, et al. Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy. *JAMA Netw Open*. 2022;5(1):e2144750.
89. Toh S, Li Q, Cheetham TC, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries. *Arch Womens Ment Health*. 2013;16(2):149-157.
90. Bobo WV, Davis RL, Toh S, et al. Trends in the Use of Antiepileptic Drugs among Pregnant Women in the US, 2001-2007: A Medication Exposure in Pregnancy Risk Evaluation Program Study. *Paediatr Perinat Epidemiol*. 2012;26(6):578-588.
91. Naleway AL, Irving SA, Henninger ML, et al. Safety of influenza vaccination during pregnancy: A review of subsequent maternal obstetric events and findings from two recent cohort studies. *Vaccine*. 2014;32(26):3122-3127.
92. Munoz FM, Jackson LA, Swamy GK, et al. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. *Vaccine*. 2018;36(52):8054-8061.
93. Munoz FM, Patel SM, Jackson LA, et al. Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. *Vaccine*. 2020;38(33):5355-5363.
94. Avalos LA, Ferber J, Zerbo O, et al. Trivalent inactivated influenza vaccine (IIV3) during pregnancy and six-month infant development. *Vaccine*. 2020;38(10):2326-2332.
95. Becerra-Culqui TA, Sy LS, Ackerson BK, et al. Safety of MenACWY-CRM vaccine exposure during pregnancy. *Vaccine*. 2020;38(12):2683-2690.

96. Naleway AL, Crane B, Irving SA, et al. Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. *Ther Adv Drug Saf.* 2021;12:20420986211021233.
97. Kharbanda EO, Vazquez-Benitez G, Lipkind H, et al. Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. *Obstet Gynecol.* 2013;122(3):659-667.
98. Kharbanda EO, Vazquez-Benitez G, Romitti PA, et al. First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspring. *J Pediatr.* 2017;187:234-239.
99. Nordin JD, Kharbanda EO, Vazquez-Benitez G, et al. Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse events. *Vaccine.* 2014;32(39):4985-4992.
100. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Infant Hospitalizations and Mortality After Maternal Vaccination. *Pediatrics.* 2018;141(3):02.
101. Panagiotakopoulos L, McCarthy NL, Tepper NK, et al. Evaluating the Association of Stillbirths After Maternal Vaccination in the Vaccine Safety Datalink. *Obstet Gynecol.* 2020;136(6):1086-1094.
102. Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. *Vaccine.* 2016;34(7):968-973.
103. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. *JAMA.* 2015;314(15):1581-1587.
104. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. *Obstet Gynecol.* 2015;126(5):1069-1074.
105. Tseng HF, Sy LS, Ackerson BK, et al. Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy. *Vaccine.* 2022;40(32):4503-4512.
106. Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. *JAMA.* 2014;312(18):1897-1904.
107. Groom HC, Irving SA, Koppolu P, et al. Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. *Vaccine.* 2018;36(41):6111-6116.
108. Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy. *Obstet Gynecol.* 2018;132(1):35-44.
109. Lipkind HS, Vazquez-Benitez G, Nordin JD, et al. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. *Obstet Gynecol.* 2017;130(3):599-608.
110. Kharbanda EO, Vazquez-Benitez G, DeSilva MB, et al. Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. *JAMA Netw Open.* 2021;4(4):e214340.
111. Kharbanda EO, Haapala J, DeSilva M, et al. Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy. *JAMA.* 2021;326(16):1629-1631.
112. Lipkind HS, Vazquez-Benitez G, DeSilva M, et al. Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth - Eight Integrated Health Care Organizations, United States, December 15, 2020-July 22, 2021. *MMWR Morb Mortal Wkly Rep.* 2022;71(1):26-30.
113. Vazquez-Benitez G, Haapala JL, Lipkind HS, et al. COVID-19 Vaccine Safety Surveillance in Early Pregnancy in the United States: Design Factors Affecting the Association Between Vaccine and Spontaneous Abortion. *Am J Epidemiol.* 2023.
114. Gunderson EP, Jacobs DR, Jr., Chiang V, et al. Childbearing is associated with higher incidence of the metabolic syndrome among women of reproductive age controlling for measurements before pregnancy: the CARDIA study. *Am J Obstet Gynecol.* 2009;201(2):177.e171-179.
115. Getahun D, Fassett MJ, Jacobsen SJ. Gestational diabetes: risk of recurrence in subsequent pregnancies. *Am J Obstet Gynecol.* 2010;203(5):467.e461-466.
116. Sridhar SB, Xu F, Darbinian J, et al. Pregravid Liver Enzyme Levels and Risk of Gestational Diabetes During a Subsequent Pregnancy. *Diabetes Care.* 2014;37(7):1878-1884.
117. Ehrlich SF, Hedderson MM, Feng J, et al. Change in body mass index between pregnancies and the risk of gestational diabetes in a second pregnancy. *Obstet Gynecol.* 2011;117(6):1323-1330.
118. Getahun D, Ananth CV, Oyelese Y, et al. Primary preeclampsia in the second pregnancy: effects of changes in prepregnancy body mass index between pregnancies. *Obstet Gynecol.* 2007;110(6):1319-1325.
119. Getahun D, Lawrence JM, Fassett MJ, et al. The association between stillbirth in the first pregnancy and subsequent adverse perinatal outcomes. *Am J Obstet Gynecol.* 2009;201(4):378.e371-376.
120. Dunlop AL, Essalmi AG, Alvalos L, et al. Racial and geographic variation in effects of maternal education and neighborhood-level measures of socioeconomic status on gestational age at birth: Findings from the ECHO cohorts. *PLoS ONE.* 2021;16(1):e0245064.
121. Zhu Y, Hedderson MM, Feng J, et al. The Pregnancy Environment and Lifestyle Study (PETALS): a population-based longitudinal multi-racial birth cohort. *BMC Pregnancy Childbirth.* 2017;17(1):122.

122. Hedderson M, Ehrlich S, Sridhar S, et al. Racial/Ethnic Disparities in the Prevalence of Gestational Diabetes by BMI. *Diabetes Care*. 2012;35(7):1492-1498.
123. Hedderson MM, Darbinian JA, Ferrara A. Disparities in the risk of gestational diabetes by race-ethnicity and country of birth. *Paediatr Perinat Epidemiol*. 2010;24(5):441-448.
124. Caughey AB, Cheng YW, Stotland NE, et al. Maternal and paternal race/ethnicity are both associated with gestational diabetes. *Am J Obstet Gynecol*. 2010;202(6):616.e611-615.
125. Shah NS, Wang MC, Freaney PM, et al. Trends in Gestational Diabetes at First Live Birth by Race and Ethnicity in the US, 2011-2019. *JAMA*. 2021;326(7):660-669.
126. Getahun D, Nath C, Ananth CV, et al. Gestational diabetes in the United States: temporal trends 1989 through 2004. *Am J Obstet Gynecol*. 2008;198(5):525.e521-525.
127. Shah NS, Wang MC, Kandula NR, et al. Gestational Diabetes and Hypertensive Disorders of Pregnancy by Maternal Birthplace. *Am J Prev Med*. 2022;62(4):e223-e231.
128. Gunderson EP, Greenberg M, Nguyen-Huynh MN, et al. Early Pregnancy Blood Pressure Patterns Identify Risk of Hypertensive Disorders of Pregnancy Among Racial and Ethnic Groups. *Hypertension*. 2022;79(3):599-613.
129. Wellons MF, Lewis CE, Schwartz SM, et al. Racial differences in self-reported infertility and risk factors for infertility in a cohort of black and white women: the CARDIA Women's Study. *Fertil Steril*. 2008;90(5):1640-1648.
130. Xiang AH, Li BH, Black MH, et al. Racial and ethnic disparities in diabetes risk after gestational diabetes mellitus. *Diabetologia*. 2011;54(12):3016-3021.
131. Sridhar SB, Ferrara A, Ehrlich SF, et al. Risk of Large-for-Gestational-Age Newborns in Women With Gestational Diabetes by Race and Ethnicity and Body Mass Index Categories. *Obstet Gynecol*. 2013;121(6):1255-1262.
132. Xiang AH, Black MH, Li BH, et al. Racial and ethnic disparities in extremes of fetal growth after gestational diabetes mellitus. *Diabetologia*. 2015;58(2):272-281.
133. Sauder KA, Harte RN, Ringham BM, et al. Disparities in Risks of Inadequate and Excessive Intake of Micronutrients during Pregnancy. *J Nutr*. 2021;151(11):3555-3569.
134. Zhu Y, Hedderson MM, Sridhar S, et al. Poor diet quality in pregnancy is associated with increased risk of excess fetal growth: a prospective multi-racial/ethnic cohort study. *Int J Epidemiol*. 2019;48(2):423-432.
135. Zhu Y, Olsen SF, Mendola P, et al. Maternal consumption of artificially sweetened beverages during pregnancy, and offspring growth through 7 years of age: a prospective cohort study. *Int J Epidemiol*. 2017;46(5):1499-1508.
136. Chen Z, Watanabe RM, Stram DO, et al. High Calorie Intake Is Associated With Worsening Insulin Resistance and B-Cell Function in Hispanic Women After Gestational Diabetes Mellitus. *Diabetes Care*. 2014;37(12):3294-3300.
137. Davis JN, Shearrer GE, Tao W, et al. Dietary variables associated with substantial postpartum weight retention at 1-year among women with GDM pregnancy. *BMC Obes*. 2017;4:31.
138. Hedderson MM, Xu F, Sridhar SB, et al. Mediating Effects of Cardiometabolic Risk Factors on the Association Between Maternal Race-Ethnicity and Cesarean Delivery Among Low-Risk Women. *J Womens Health (Larchmt)*. 2021;30(7):1028-1037.
139. Hedderson MM, Xu F, Dayo OM, et al. Contribution of Maternal Cardiometabolic Risk Factors to Racial-Ethnicity Disparities in Preterm Birth Subtypes. *Am J Obstet Gynecol MFM*. 2022;4(3):100608.
140. Bekkar B, Pacheco S, Basu R, DeNicola N. Association of Air Pollution and Heat Exposure With Preterm Birth, Low Birth Weight, and Stillbirth in the US: A Systematic Review. *JAMA Netw Open*. 2020;3(6):e208243.
141. Sun Y, Sheridan P, Laurent O, et al. Associations between green space and preterm birth: Windows of susceptibility and interaction with air pollution. *Environ Int*. 2020;142:105804.
142. Peltier MR, Fassett MJ, Arita Y, et al. Women with high plasma levels of PBDE-47 are at increased risk of preterm birth. *J Perinat Med*. 2021;49(4):439-447.
143. Sun Y, Li X, Benmarhnia T, et al. Exposure to air pollutant mixture and gestational diabetes mellitus in Southern California: Results from electronic health record data of a large pregnancy cohort. *Environ Int*. 2021;158:106888.
144. Kubo A, Ferrara A, Brown SD, et al. Perceived psychosocial stress and gestational weight gain among women with gestational diabetes. *PLoS ONE*. 2017;12(3):e0174290.
145. Hassert S, Kurpius SE, Tracey TJ. Testing a Conceptual Model of Postpartum Depressive Symptoms in the First Year. *Women Health*. 2015;55(6):700-716.
146. Avalos LA, Nance N, Zhu Y, et al. Contributions of COVID-19 Pandemic-Related Stressors to Racial and Ethnic Disparities in Mental Health During Pregnancy. *Front Psychiatry*. 2022;13:837659.
147. Bennett WL, Liu SH, Yeh HC, et al. Changes in weight and health behaviors after pregnancies complicated by gestational diabetes mellitus: The CARDIA study. *Obesity (Silver Spring)*. 2013;21(6):1269-1275.
148. Vesco KK, Dietz PM, Rizzo J, et al. Excessive gestational weight gain and postpartum weight retention among obese women. *Obstet Gynecol*. 2009;114(5):1069-1075.

149. Hutchins F, Abrams B, Brooks M, et al. The Effect of Gestational Weight Gain Across Reproductive History on Maternal Body Mass Index in Midlife: The Study of Women's Health Across the Nation. *J Womens Health (Larchmt)*. 2020;29(2):148-157.
150. Gunderson EP, Lewis CE, Tsai AL, et al. A 20-year prospective study of childbearing and incidence of diabetes in young women, controlling for glycemia before conception: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. *Diabetes*. 2007;56(12):2990-2996.
151. Lowe WL, Scholtens DM, Lowe LP, et al. Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity. *JAMA*. 2018;320(10):1005-1016.
152. Xiang AH, Kjos SL, Takayanagi M, et al. Detailed physiological characterization of the development of type 2 diabetes in Hispanic women with prior gestational diabetes mellitus. *Diabetes*. 2010;59(10):2625-2630.
153. Lai M, Al Rijjal D, Röst HL, et al. Underlying dyslipidemia postpartum in women with a recent GDM pregnancy who develop type 2 diabetes. *Elife*. 2020;9:08.
154. Gunderson EP. Childbearing and obesity in women: weight before, during, and after pregnancy. *Obstet Gynecol Clin North Am*. 2009;36(2):317-332.
155. Black MH, Zhou H, Sacks DA, et al. Hypertensive disorders first identified in pregnancy increase risk for incident prehypertension and hypertension in the year after delivery. *J Hypertens*. 2016;34(4):728-735.
156. Catov JM, Lewis CE, Lee M, et al. Preterm Birth and Future Maternal Blood Pressure, Inflammation, and Intimal-medial Thickness: The CARDIA Study. *Hypertension*. 2013;61(3):641-646.
157. Kirkegaard H, Bliddal M, Støvring H, et al. Maternal weight change from prepregnancy to 18 months postpartum and subsequent risk of hypertension and cardiovascular disease in Danish women: A cohort study. *PLoS Med*. 2021;18(4):e1003486.
158. Appiah D, Schreiner PJ, Gunderson EP, et al. The Association of Gestational Diabetes Mellitus With Left Ventricular Structure and Function: The CARDIA Study. *Diabetes Care*. 2016;39(3):400-407.
159. Sun B, Bertolet M, Brooks MM, et al. Life Course Changes in Cardiometabolic Risk Factors Associated With Preterm Delivery: The 30-Year CARDIA Study. *J Am Heart Assoc*. 2020;9(15):e015900.
160. Lowe LP, Perak AM, Kuang A, et al. Associations of glycemia and lipid levels in pregnancy with dyslipidemia 10-14 years later: The HAPO follow-up study. *Diabetes Res Clin Pract*. 2022;185:109790.
161. Ajmera VH, Gunderson EP, VanWagner LB, et al. Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. *Am J Gastroenterol*. 2016;111(5):658-664.
162. Dehmer EW, Phadnis MA, Gunderson EP, et al. Association Between Gestational Diabetes and Incident Maternal CKD: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. *Am J Kidney Dis*. 2018;71(1):112-122.
163. Gilbert AL, Prasad S, Mallery RM. Neuro-Ophthalmic Disorders in Pregnancy. *Neurol Clin*. 2019;37(1):85-102.
164. Kim C, McEwen LN, Kerr EA, et al. Preventive counseling among women with histories of gestational diabetes mellitus. *Diabetes Care*. 2007;30(10):2489-2495.
165. Tom JO, Tseng CW, Davis J, et al. Missed well-child care visits, low continuity of care, and risk of ambulatory care-sensitive hospitalizations in young children. *Arch Pediatr Adolesc Med*. 2010;164(11):1052-1058.
166. Bruce FC, Berg CJ, Hornbrook MC, et al. Maternal morbidity rates in a managed care population. *Obstet Gynecol*. 2008;111(5):1089-1095.
167. Bruce FC, Berg CJ, Joski PJ, et al. Extent of maternal morbidity in a managed care population in georgia. *Paediatr Perinat Epidemiol*. 2012;26(6):497-505.
168. Britton JR. Infant temperament and maternal anxiety and depressed mood in the early postpartum period. *Women Health*. 2011;51(1):55-71.
169. Metz TD, Rovner P, Hoffman MC, et al. Maternal Deaths From Suicide and Overdose in Colorado, 2004-2012. *Obstet Gynecol*. 2016;128(6):1233-1240.
170. Catalano PM, Sacks DA. Timing of indicated late preterm and early-term birth in chronic medical complications: diabetes. *Semin Perinatol*. 2011;35(5):297-301.
171. Hillier TA, Pedula KL, Schmidt MM, et al. Childhood obesity and metabolic imprinting: the ongoing effects of maternal hyperglycemia. *Diabetes Care*. 2007;30(9):2287-2292.
172. Sridhar SB, Darbinian J, Ehrlich SF, et al. Maternal gestational weight gain and offspring risk for childhood overweight or obesity. *Am J Obstet Gynecol*. 2014;211(3):259.e251-258.
173. Kaar JL, Crume T, Brinton JT, et al. Maternal Obesity, Gestational Weight Gain, and Offspring Adiposity: The Exploring Perinatal Outcomes among Children Study. *J Pediatr*. 2014;165(3):509-515.
174. Kubo A, Ferrara A, Windham GC, et al. Maternal Hyperglycemia During Pregnancy Predicts Adiposity of the Offspring. *Diabetes Care*. 2014;37(11):2996-3002.
175. Bider-Canfield Z, Martinez MP, Wang X, et al. Maternal obesity, gestational diabetes, breastfeeding and childhood overweight at age 2 years. *Pediatr Obes*. 2017;12(2):171-178.
176. Hillier TA, Pedula KL, Vesco KK, et al. Impact of Maternal Glucose and Gestational Weight Gain on Child Obesity over the First Decade of Life in Normal Birth Weight Infants. *Matern Child Health J*. 2016;20(8):1559-1568.

177. Li S, Zhu Y, Yeung E, et al. Offspring risk of obesity in childhood, adolescence and adulthood in relation to gestational diabetes mellitus: a sex-specific association. *Int J Epidemiol*. 2017;46(5):1533-1541.
178. Crume TL, Ogden L, West NA, et al. Association of exposure to diabetes in utero with adiposity and fat distribution in a multiethnic population of youth: the Exploring Perinatal Outcomes among Children (EPOCH) Study. *Diabetologia*. 2011;54(1):87-92.
179. Page KA, Romero A, Buchanan TA, Xiang AH. Gestational Diabetes Mellitus, Maternal Obesity, and Adiposity in Offspring. *J Pediatr*. 2014;164(4):807-810.
180. Pham MT, Brubaker K, Pruett K, Caughey AB. Risk of childhood obesity in the toddler offspring of mothers with gestational diabetes. *Obstet Gynecol*. 2013;121(5):976-982.
181. Lowe WL, Lowe LP, Kuang A, et al. Maternal glucose levels during pregnancy and childhood adiposity in the Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study. *Diabetologia*. 2019;62(4):598-610.
182. Ehrlich SF, Hedderson MM, Xu F, Ferrara A. Diagnostic thresholds for pregnancy hyperglycemia, maternal weight status and the risk of childhood obesity in a diverse Northern California cohort using health care delivery system data. *PLoS ONE*. 2019;14(5):e0216897.
183. Wang X, Martinez MP, Chow T, Xiang AH. BMI growth trajectory from ages 2 to 6 years and its association with maternal obesity, diabetes during pregnancy, gestational weight gain, and breastfeeding. *Pediatr Obes*. 2020;15(2):e12579.
184. MacDonald KD, Vesco KK, Funk KL, et al. Maternal body mass index before pregnancy is associated with increased bronchodilator dispensing in early childhood: A cross-sectional study. *Pediatr Pulmonol*. 2016;51(8):803-811.
185. Shah J, Shadid ILC, Carey VJ, et al. Early Life Weight Status and Risk of Childhood Asthma or Recurrent Wheeze in Preterm and Term Offspring. *J Allergy Clin Immunol Pract*. 2023.
186. Song Y, Huang YT, Song Y, et al. Birthweight, mediating biomarkers and the development of type 2 diabetes later in life: a prospective study of multi-ethnic women. *Diabetologia*. 2015;58(6):1220-1230.
187. Catov JM, Althouse AD, Lewis CE, et al. Preterm Delivery and Metabolic Syndrome in Women Followed From Prepregnancy Through 25 Years Later. *Obstet Gynecol*. 2016;127(6):1127-1134.
188. Madsen LR, Gibbons KS, Ma RCW, et al. Do variations in insulin sensitivity and insulin secretion in pregnancy predict differences in obstetric and neonatal outcomes? *Diabetologia*. 2021;64(2):304-312.
189. Getahun D, Strickland D, Zeiger RS, et al. Effect of chorioamnionitis on early childhood asthma. *Arch Pediatr Adolesc Med*. 2010;164(2):187-192.
190. Mirzakhani H, Carey VJ, McElrath TF, et al. Impact of Preeclampsia on the Relationship of Maternal Asthma with Offspring Asthma: An Observation from the VDAART Clinical Trial. *Am J Respir Crit Care Med*. 2019;199(1):32-42.
191. Getahun D, Fassett MJ, Peltier MR, et al. Association of Perinatal Risk Factors with Autism Spectrum Disorder. *Am J Perinatol*. 2017;34(3):295-304.
192. Windham GC, Anderson M, Lyall K, et al. Maternal Pre-pregnancy Body Mass Index and Gestational Weight Gain in Relation to Autism Spectrum Disorder and other Developmental Disorders in Offspring. *Autism Res*. 2019;12(2):316-327.
193. Getahun D, Jacobsen SJ, Fassett MJ, et al. Association between maternal hypothyroidism and autism spectrum disorders in children. *Pediatr Res*. 2018;83(3):580-588.
194. Getahun D, Rhoads GG, Demissie K, et al. In Utero Exposure to Ischemic-Hypoxic Conditions and Attention-Deficit/Hyperactivity Disorder. *Pediatrics*. 2013;131(1):e53-61.
195. Xiang AH, Wang X, Martinez MP, et al. Maternal Gestational Diabetes Mellitus, Type 1 Diabetes, and Type 2 Diabetes During Pregnancy and Risk of ADHD in Offspring. *Diabetes Care*. 2018;41(12):2502-2508.
196. Davis RL, Eastman D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. *Pharmacoepidemiol Drug Saf*. 2011;20(2):138-145.
197. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. *Pharmacoepidemiol Drug Saf*. 2007;16(10):1086-1094.
198. Petrini JR, Dias T, McCormick MC, et al. Increased risk of adverse neurological development for late preterm infants. *J Pediatr*. 2009;154(2):169-176.
199. Lyall K, Croen LA, Sjödin A, et al. Polychlorinated Biphenyl and Organochlorine Pesticide Concentrations in Maternal Mid-Pregnancy Serum Samples: Association with Autism Spectrum Disorder and Intellectual Disability. *Environ Health Perspect*. 2017;125(3):474-480.
200. McGuinn LA, Windham GC, Kalkbrenner AE, et al. Early Life Exposure to Air Pollution and Autism Spectrum Disorder: Findings from a Multisite Case-Control Study. *Epidemiology*. 2020;31(1):103-114.
201. Rahman MM, Shu YH, Chow T, et al. Prenatal Exposure to Air Pollution and Autism Spectrum Disorder: Sensitive Windows of Exposure and Sex Differences. *Environ Health Perspect*. 2022;130(1):17008.

202. Carter SA, Rahman MM, Lin JC, et al. In utero exposure to near-roadway air pollution and autism spectrum disorder in children. *Environ Int.* 2022;158:106898.
203. Rahman MM, Carter SA, Lin JC, et al. Associations of Autism Spectrum Disorder with PM2.5 Components: A Comparative Study Using Two Different Exposure Models. *Environ Sci Technol.* 2023;57(1):405-414.
204. Rahman MM, Carter SA, Lin JC, et al. Prenatal exposure to tailpipe and non-tailpipe tracers of particulate matter pollution and autism spectrum disorders. *Environ Int.* 2023;171:107736.
205. Padula AM, Ning X, Bakre S, et al. Birth Outcomes in Relation to Prenatal Exposure to Per- and Polyfluoroalkyl Substances and Stress in the Environmental Influences on Child Health Outcomes (ECHO) Program. *Environ Health Perspect.* 2023;131(3):37006.
206. Braunschweig D, Ashwood P, Krakowiak P, et al. Autism: maternally derived antibodies specific for fetal brain proteins. *Neurotoxicology.* 2008;29(2):226-231.
207. Jones KL, Croen LA, Yoshida CK, et al. Autism with intellectual disability is associated with increased levels of maternal cytokines and chemokines during gestation. *Mol Psychiatry.* 2017;22(2):273-279.
208. Traglia M, Croen LA, Jones KL, et al. Cross-genetic determination of maternal and neonatal immune mediators during pregnancy. *Genome Med.* 2018;10(1):67.
209. Croen LA, Qian Y, Ashwood P, et al. Family history of immune conditions and autism spectrum and developmental disorders: Findings from the study to explore early development. *Autism Res.* 2019;12(1):123-135.
210. Zerbo O, Iosif AM, Walker C, et al. Is Maternal Influenza or Fever During Pregnancy Associated with Autism or Developmental Delays? Results from the CHARGE (Childhood Autism Risks from Genetics and Environment) Study. *J Autism Dev Disord.* 2013;43(1):25-33.
211. Zerbo O, Qian Y, Yoshida C, et al. Maternal Infection During Pregnancy and Autism Spectrum Disorders. *J Autism Dev Disord.* 2015;45(12):4015-4025.
212. Croen LA, Qian Y, Ashwood P, et al. Infection and Fever in Pregnancy and Autism Spectrum Disorders: Findings from the Study to Explore Early Development. *Autism Res.* 2019;12(10):1551-1561.
213. Xiang AH, Wang X, Martinez MP, et al. Association of maternal diabetes with autism in offspring. *JAMA.* 2015;313(14):1425-1434.
214. Lyall K, Ning X, Aschner JL, et al. Cardiometabolic Pregnancy Complications in Association with Autism-Related Traits as Measured by the Social Responsiveness Scale in ECHO. *Am J Epidemiol.* 2022;191(8):1407-1419.
215. Kuzniewicz MW, Wi S, Qian Y, et al. Prevalence and Neonatal Factors Associated with Autism Spectrum Disorders in Preterm Infants. *J Pediatr.* 2014;164(1):20-25.
216. Rubenstein E, Young JC, Croen LA, et al. Brief Report: Maternal Opioid Prescription from Preconception Through Pregnancy and the Odds of Autism Spectrum Disorder and Autism Features in Children. *J Autism Dev Disord.* 2019;49(1):376-382.
217. Hansen C, Adams M, Fox DJ, et al. Exploring the feasibility of using electronic health records in the surveillance of fetal alcohol syndrome. *Birth Defects Res Part A Clin Mol Teratol.* 2014;100(2):67-78.
218. Singer AB, Aylsworth AS, Cordero C, et al. Prenatal Alcohol Exposure in Relation to Autism Spectrum Disorder: Findings from the Study to Explore Early Development (SEED). *Paediatr Perinat Epidemiol.* 2017;31(6):573-582.
219. Brouwer L, Vogels T, Taal E, et al. Long term follow-up of health-related quality of life in young adults born very preterm or with a very low birth weight. *Health Qual Life Outcomes.* 2012;10:49.
220. Lakshmanan A, Agni M, Lieu T, et al. The impact of preterm birth <37 weeks on parents and families: a cross-sectional study in the 2 years after discharge from the neonatal intensive care unit. *Health Qual Life Outcomes.* 2017;15(1):38.
221. Holman-Vittone A, Monahan B, LeBlanc ES, et al. Associations of maternal preterm birth with subsequent risk for type 2 diabetes in women from the women's health initiative. *J Dev Orig Health Dis.* 2023;14(3):333-340.
222. Vahratian A, Barber JS, Lawrence JM, Kim C. Family-planning practices among women with diabetes and overweight and obese women in the 2002 National Survey For Family Growth. *Diabetes Care.* 2009;32(6):1026-1031.
223. Postlethwaite D, Armstrong MA, Hung YY, Shaber R. Pregnancy outcomes by pregnancy intention in a managed care setting. *Matern Child Health J.* 2010;14(2):227-234.
224. Harrison TN, Sacks DA, Parry C, et al. Acceptability of Virtual Prenatal Visits for Women with Gestational Diabetes. *Womens Health Issues.* 2017;27(3):351-355.
225. Woo VG, Lundeen T, Matula S, Milstein A. Achieving Higher-Value Obstetrical Care. *Am J Obstet Gynecol.* 2017;216(3):250.e251-250.
226. Muoto I, Luck J, Yoon J, et al. Oregon's Coordinated Care Organizations Increased Timely Prenatal Care Initiation And Decreased Disparities. *Health Aff (Millwood).* 2016;35(9):1625-1632.
227. Eden KB, Dolan JG, Perrin NA, et al. Patients were more consistent in randomized trial at prioritizing childbirth preferences using graphic-numeric than verbal formats. *J Clin Epidemiol.* 2009;62(4):415-424.

228. Dietz PM, Rizzo JH, England LJ, et al. Health Care Utilization in the First Year of Life among Small- and Large-for-Gestational Age Term Infants. *Matern Child Health J.* 2013;17(6):1016-1024.
229. Flaherman VJ, Schaefer EW, Kuzniewicz MW, et al. Early weight loss nomograms for exclusively breastfed newborns. *Pediatrics.* 2015;135(1):e16-23.
230. Gunderson EP. Breast-feeding and diabetes: long-term impact on mothers and their infants. *Curr Diab Rep.* 2008;8(4):279-286.
231. Gunderson EP, Hurston SR, Dewey KG, et al. The study of women, infant feeding and type 2 diabetes after GDM pregnancy and growth of their offspring (SWIFT Offspring study): prospective design, methodology and baseline characteristics. *BMC Pregnancy Childbirth.* 2015;15:150.
232. Crume TL, Ogden L, Maligie M, et al. Long-term impact of neonatal breastfeeding on childhood adiposity and fat distribution among children exposed to diabetes in utero. *Diabetes Care.* 2011;34(3):641-645.
233. Gunderson EP, Greenspan LC, Faith MS, et al. Breastfeeding and growth during infancy among offspring of mothers with gestational diabetes mellitus: a prospective cohort study. *Pediatr Obes.* 2018;13(8):492-504.
234. Vandyousefi S, Goran MI, Gunderson EP, et al. Association of breastfeeding and gestational diabetes mellitus with the prevalence of prediabetes and the metabolic syndrome in offspring of Hispanic mothers. *Pediatr Obes.* 2019;14(7):e12515.
235. Flaherman VJ, Aby J, Burgos AE, et al. Effect of Early Limited Formula on Duration and Exclusivity of Breast-feeding in At-Risk Infants: An RCT. *Pediatrics.* 2013;131(6):1059-1065.
236. Patnode CD, Henninger ML, Senger CA, et al. Primary Care Interventions to Support Breastfeeding: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2016;316(16):1694-1705.
237. Teigen NC, Sahasrabudhe N, Doulaveris G, et al. Enhanced Recovery after Surgery (ERAS) at Cesarean to Reduce Postoperative Length of Stay: A Randomized Controlled Trial. *Am J Obstet Gynecol.* 2020;222(4):372.e371-372.
238. O'Connor E, Rossom RC, Henninger M, et al. Primary Care Screening for and Treatment of Depression in Pregnant and Postpartum Women: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2016;315(4):388-406.
239. Avalos LA, Raine-Bennett T, Chen H, et al. Improved Perinatal Depression Screening, Treatment, and Outcomes With a Universal Obstetric Program. *Obstet Gynecol.* 2016;127(5):917-925.
240. Flanagan T, Avalos LA. Perinatal Obstetric Office Depression Screening and Treatment: Implementation in a Health Care System. *Obstet Gynecol.* 2016;127(5):911-915.
241. Henderson JT, Thompson JH, Burda BU, Cantor A. Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2017;317(16):1668-1683.
242. U. S. Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2017;317(16):1661-1667.
243. Hillier TA, Ogasawara KK, Pedula KL, Vesco KK. Markedly different rates of incident insulin treatment based on universal gestational diabetes mellitus screening in a diverse HMO population. *Am J Obstet Gynecol.* 2013;209(5):440.e441-449.
244. Hillier TA, Vesco KK, Pedula KL, et al. Screening for gestational diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2008;148(10):766-775.
245. Vesco KK, Dietz PM, Bulkley J, et al. A system-based intervention to improve postpartum diabetes screening among women with gestational diabetes. *Am J Obstet Gynecol.* 2012;207(4):283.e281-286.
246. Hillier TA, Pedula KL, Ogasawara KK, et al. Impact of earlier gestational diabetes screening for pregnant people with obesity on maternal and perinatal outcomes. *J Perinat Med.* 2022;50(8):1036-1044.
247. Feldman RK, Tieu RS, Yasumura L. Gestational Diabetes Screening: The International Association of the Diabetes and Pregnancy Study Groups Compared With Carpenter-Coustan Screening. *Obstet Gynecol.* 2016;127(1):10-17.
248. Pocobelli G, Yu O, Fuller S, et al. One-Step Approach to Identifying Gestational Diabetes Mellitus: Association With Perinatal Outcomes. *Obstet Gynecol.* 2018;132(4):859-867.
249. Hillier TA, Pedula KL, Ogasawara KK, et al. A Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening. *N Engl J Med.* 2021;384(10):895-904.
250. Ferrara A, Peng T, Kim C. Trends in postpartum diabetes screening and subsequent diabetes and impaired fasting glucose among women with histories of gestational diabetes mellitus: A report from the Translating Research Into Action for Diabetes (TRIAD) Study. *Diabetes Care.* 2009;32(2):269-274.
251. Dietz PM, Vesco KK, Callaghan WM, et al. Postpartum screening for diabetes after a gestational diabetes mellitus-affected pregnancy. *Obstet Gynecol.* 2008;112(4):868-874.
252. Brown SD, Hedderson MM, Zhu Y, et al. Uptake of guideline-recommended postpartum diabetes screening among diverse women with gestational diabetes: associations with patient factors in an integrated health system in USA. *BMJ Open Diabetes Res Care.* 2022;10(3):e002726.

253. Ehrlich SF, Sternfeld B, Krefman AE, et al. Moderate and Vigorous Intensity Exercise During Pregnancy and Gestational Weight Gain in Women with Gestational Diabetes. *Matern Child Health J.* 2016;20(6):1247-1257.
254. LeBlanc ES, Vesco KK, Funk KL, et al. Prepare, a randomized trial to promote and evaluate weight loss among overweight and obese women planning pregnancy: Study design and rationale. *Contemp Clin Trials.* 2016;49:174-180.
255. Ferrara A, Hedderson MM, Albright CL, et al. A pregnancy and postpartum lifestyle intervention in women with gestational diabetes mellitus reduces diabetes risk factors: a feasibility randomized control trial. *Diabetes Care.* 2011;34(7):1519-1525.
256. Ehrlich SF, Hedderson MM, Brown SD, et al. Moderate intensity sports and exercise is associated with glycaemic control in women with gestational diabetes. *Diabetes Metab.* 2017;43(5):416-423.
257. Vesco KK, Karanja N, King JC, et al. Efficacy of a group-based dietary intervention for limiting gestational weight gain among obese women: A randomized trial. *Obesity (Silver Spring).* 2014;22(9):1989-1996.
258. Leblanc ES, Smith NX, Vesco KK, et al. Weight Loss Prior to Pregnancy and Subsequent Gestational Weight Gain: Prepare, a Randomized Clinical Trial. *Am J Obstet Gynecol.* 2021;224(1):99.e91-99.e14.
259. Thomas T, Xu F, Sridhar S, et al. A Web-Based mHealth Intervention With Telephone Support to Increase Physical Activity Among Pregnant Patients With Overweight or Obesity: Feasibility Randomized Controlled Trial. *JMIR Form Res.* 2022;6(6):e33929.
260. Vesco KK, Karanja N, King JC, et al. Healthy Moms, a randomized trial to promote and evaluate weight maintenance among obese pregnant women: Study design and rationale. *Contemp Clin Trials.* 2012;33(4):777-785.
261. Zhu Y, Olsen SF, Mendola P, et al. Maternal dietary intakes of refined grains during pregnancy and growth through the first 7 y of life among children born to women with gestational diabetes. *Am J Clin Nutr.* 2017;106(1):96-104.
262. Ferrara A, Hedderson MM, Ching J, et al. Referral to telephonic nurse management improves outcomes in women with gestational diabetes. *Am J Obstet Gynecol.* 2012;206(6):491.e491-495.
263. Flanagan T, Alabaster A, McCaw B, et al. Feasibility and Acceptability of Screening for Adverse Childhood Experiences in Prenatal Care. *J Womens Health (Larchmt).* 2018;27(7):903-911.
264. Nayak MB, Korcha RA, Kaskustas LA, Avalos LA. Feasibility and acceptability of a novel, computerized screening and brief intervention (SBI) for alcohol and sweetened beverage use in pregnancy. *BMC Pregnancy Childbirth.* 2014;14:379.
265. Taillac C, Goler N, Armstrong MA, et al. Early start: an integrated model of substance abuse intervention for pregnant women. *Perm J.* 2007;11(3):5-11.
266. Witbrodt J, Armstrong MA, Diehl S, et al. Using drink size to talk about drinking during pregnancy: Early start plus. *J Addict Nurs.* 2007;18(4):199-206.
267. Goler NC, Armstrong MA, Taillac CJ, Osejo VM. Substance abuse treatment linked with prenatal visits improves perinatal outcomes: a new standard. *J Perinatol.* 2008;28(9):597-603.
268. Young-Wolff KC, Tucker LY, Armstrong MA, et al. Correlates of Pregnant Women's Participation in a Substance Use Assessment and Counseling Intervention Integrated into Prenatal Care. *Matern Child Health J.* 2020;24(4):423-431.
269. Patnode CD, Henderson JT, Thompson JH, et al. Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviews for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2015;163(8):608-621.
270. Armstrong MA, Kaskustas LA, Witbrodt J, et al. Using drink size to talk about drinking during pregnancy: a randomized clinical trial of Early Start Plus. *Soc Work Health Care.* 2009;48(1):90-103.
271. Kozhimannil KB, Adams AS, Soumerai SB, et al. New Jersey's efforts to improve postpartum depression care did not change treatment patterns for women on medicaid. *Health Aff (Millwood).* 2011;30(2):293-301.
272. Dimidjian S, Goodman SH, Felder JN, et al. Staying Well During Pregnancy and the Postpartum: A Pilot Randomized Trial of Mindfulness-Based Cognitive Therapy for the Prevention of Depressive Relapse/Recurrence. *J Consult Clin Psychol.* 2016;84(2):134-145.
273. Dimidjian S, Goodman SH, Sherwood NE, et al. A pragmatic randomized clinical trial of behavioral activation for depressed pregnant women. *J Consult Clin Psychol.* 2017;85(1):26-36.
274. Grote NK, Simon GE, Russo J, et al. Incremental Benefit-Cost of MOMCare: Collaborative Care for Perinatal Depression Among Economically Disadvantaged Women. *Psychiatr Serv.* 2017;68(11):1164-1171.
275. Ferrara A, Hedderson MM, Brown SD, et al. The Comparative Effectiveness of Diabetes Prevention Strategies to Reduce Postpartum Weight Retention in Women With Gestational Diabetes Mellitus: The Gestational Diabetes' Effects on Moms (GEM) Cluster Randomized Controlled Trial. *Diabetes Care.* 2016;39(1):65-74.
276. Glanz JM, Wagner NM, Narwaney KJ, et al. Web-based Social Media Intervention to Increase Vaccine Acceptance: A Randomized Controlled Trial. *Pediatrics.* 2017;140(6):11.
277. Opel DJ, Zhou C, Robinson JD, et al. Impact of the Childhood Vaccine Discussion Format Over Time on Immunization Status. *Acad Pediatr.* 2018;18(4):430-436.

278. Daley MF, Narwaney KJ, Shoup JA, et al. Addressing Parents' Vaccine Concerns: A Randomized Trial of a Social Media Intervention. *Am J Prev Med.* 2018;55(1):44-54.
279. Glanz JM, Kraus CR, Daley MF. Addressing Parental Vaccine Concerns: Engagement, Balance, and Timing. *PLoS Biol.* 2015;13(8):e1002227.
280. Shoup JA, Wagner NM, Kraus CR, et al. Development of an interactive social media tool for parents with concerns about vaccines. *Health Educ Behav.* 2015;42(3):302-312.
281. Schoeppe J, Cheadle A, Melton M, et al. The Immunity Community: A Community Engagement Strategy for Reducing Vaccine Hesitancy. *Health Promot Pract.* 2017;18(5):654-661.
282. Kozhimannil KB, Trinacty CM, Busch AB, et al. Racial and ethnic disparities in postpartum depression care among low-income women. *Psychiatr Serv.* 2011;62(6):619-625.
283. Lorch SA, Wade KC, Bakewell-Sachs S, et al. Racial differences in the use of respiratory medications in premature infants after discharge from the neonatal intensive care unit. *J Pediatr.* 2007;151(6):604-610.
284. Fuentes-Afflick E, Odouli R, Escobar GJ, et al. Maternal Acculturation and the Prenatal Care Experience. *J Womens Health (Larchmt).* 2014;23(8):688-706.
285. Perdion K, Lesser R, Hirsch J, et al. A midwifery-led in-hospital birth center within an academic medical center: successes and challenges. *J Perinat Neonatal Nurs.* 2013;27(4):302-310.
286. Bello NA, Zhou H, Cheatham TC, et al. Prevalence of Hypertension Among Pregnant Women When Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines and Association With Maternal and Fetal Outcomes. *JAMA Netw Open.* 2021;4(3):e213808.
287. Hedderson MM, Brown SD, Ehrlich SF, et al. A Tailored Letter Based on Electronic Health Record Data Improves Gestational Weight Gain Among Women With Gestational Diabetes: The Gestational Diabetes' Effects on Moms (GEM) Cluster-Randomized Controlled Trial. *Diabetes Care.* 2018;41(7):1370-1377.
288. Ferrara A, Hedderson MM, Brown SD, et al. A telehealth lifestyle intervention to reduce excess gestational weight gain in pregnant women with overweight or obesity (GLOW): a randomised, parallel-group, controlled trial. *Lancet Diabetes Endocrinol.* 2020;8(6):490-500.
289. O'Leary ST, Narwaney KJ, Wagner NM, et al. Efficacy of a Web-Based Intervention to Increase Uptake of Maternal Vaccines: An RCT. *Am J Prev Med.* 2019;57(4):e125-e133.
290. Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* 2018;67(2):1-44.
291. Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* 2010;59(Rr-3):1-12.
292. Earls MF, Yogman MW, Mattson G, Rafferty J. Incorporating Recognition and Management of Perinatal Depression Into Pediatric Practice. *Pediatrics.* 2019;143(1):e20183259.
293. Obstetric Care Consensus No. 8: Interpregnancy Care. *Obstet Gynecol.* 2019;133(1):e51-e72.
294. Leffert L, Butwick A, Carvalho B, et al. The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants. *Anesth Analg.* 2018;126(3):928-944.
295. Parikh NI, Gonzalez JM, Anderson CAM, et al. Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association. *Circulation.* 2021;143(18):e902-e916.
296. U. S. Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Folic Acid Supplementation for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2017;317(2):183-189.
297. Lin JS, Eder ML, Bean SI. Screening for Syphilis Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2018;320(9):918-925.
298. Henderson JT, Whitlock EP, O'Connor E, et al. Low-Dose Aspirin for Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2014;160(10):695-703.
299. O'Connor E, Senger CA, Henninger ML, et al. Interventions to Prevent Perinatal Depression: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2019;321(6):588-601.
300. Patnode CD, Henderson JT, Coppola EL, et al. Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2021;325(3):280-298.
301. Cantor AG, Jungbauer RM, McDonagh M, et al. Counseling and Behavioral Interventions for Healthy Weight and Weight Gain in Pregnancy: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2021;325(20):2094-2109.
302. D'Alton ME, Friedman AM, Smiley RM, et al. National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. *J Obstet Gynecol Neonatal Nurs.* 2016;45(5):706-717.

303. Gregg AR, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021;23(10):1793-1806.
304. Wexler DJ, Powe CE, Barbour LA, et al. Research Gaps in Gestational Diabetes Mellitus: Executive Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. *Obstet Gynecol*. 2018;132(2):496-505.
305. Andrade SE, Davis RL, Cheetham TC, et al. Medication Exposure in Pregnancy Risk Evaluation Program. *Matern Child Health J*. 2012;16(7):1349-1354.
306. Centers for Disease Control and Prevention. Vaccine Safety Datalink (VSD). 2019; <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/>. Accessed July 11, 2019.
307. Razzaghi H, Meghani M, Pingali C, et al. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(24):895-899.
308. Schrag SJ, Verani JR, Dixon BE, et al. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. *JAMA Netw Open*. 2022;5(9):e2233273.
309. Razzaghi H, Meghani M, Crane B, et al. Receipt of COVID-19 Booster Dose Among Fully Vaccinated Pregnant Individuals Aged 18 to 49 Years by Key Demographics. *JAMA*. 2022;327(23):2351-2354.
310. U.S. Department of Health and Human Services. Environmental influences on Child Health Outcomes (ECHO) Program. <https://www.nih.gov/research-training/environmental-influences-child-health-outcomes-echo-program>. Accessed December 2, 2021.